Last reviewed · How we verify
NCT03023319
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Phase 1 trial testing Bosutinib in Carcinoma, Non-Small-Cell Lung in 6 participants. Completed in 10 May 2022.
10 May 2022
Quick facts
| Lead sponsor | Nagla Abdel Karim |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 10 December 2019 |
| Primary completion | 10 May 2022 |
| Estimated completion | 10 May 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bosutinib (bosutinib) — full drug profile →
- Pemetrexed — full drug profile →
Conditions studied
- Carcinoma, Non-Small-Cell Lung — all drugs for Carcinoma, Non-Small-Cell Lung →
- Mesothelioma — all drugs for Mesothelioma →
- Bladder Cancer — all drugs for Bladder Cancer →
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Nagla Abdel Karim
Who can join
18 and older, any sex, with Carcinoma, Non-Small-Cell Lung or Mesothelioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C, Wei Y, Wei X. · · 2019 · cited 398× · PMID 31684958 · DOI 10.1186/s12943-019-1090-3 -
Targeting Cancer Stem Cells in Triple-Negative Breast Cancer.
Park SY, Park SY, Choi JH, Nam JS. · · 2019 · cited 135× · PMID 31324052 · DOI 10.3390/cancers11070965 -
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned so Far.
Martellucci S, Clementi L, Sabetta S, Mattei V, et al · · 2020 · cited 100× · PMID 32498343 · DOI 10.3390/cancers12061448 -
Tyrosine Kinase Receptors in Oncology.
Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, et al · · 2020 · cited 72× · PMID 33198314 · DOI 10.3390/ijms21228529 -
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC, Yang CT, Jablons DM, You L. · · 2020 · cited 64× · PMID 32466572 · DOI 10.3390/cancers12061361 -
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Cantini L, Hassan R, Sterman DH, Sterman DH, et al · · 2020 · cited 47× · PMID 32226777 · DOI 10.3389/fonc.2020.00343 -
AXL signaling in cancer: from molecular insights to targeted therapies.
Yadav M, Sharma A, Patne K, Tabasum S, et al · · 2025 · cited 42× · PMID 39924521 · DOI 10.1038/s41392-024-02121-7 -
Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade.
Luttman JH, Colemon A, Mayro B, Pendergast AM. · · 2021 · cited 26× · PMID 34022881 · DOI 10.1186/s12964-021-00739-6
Verify or expand the search:
- PubMed search for NCT03023319
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bosutinib
Trials testing the same drug.
- NCT04877522 — Asciminib Roll-over Study · Phase 4 · recruiting
- NCT05032690 — Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Or · Phase 1 · completed
- NCT05363488 — Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland · completed
- NCT04971226 — A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Phase 3 · active not recruiting
- NCT05286528 — Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of · completed
Other recruiting trials for Carcinoma, Non-Small-Cell Lung
Currently open trials in the same condition.
- NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
- NCT07222566 — Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adu · Phase 3 · recruiting
- NCT07230691 — A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-Wor · recruiting
- NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
- NCT07180862 — A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03023319 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nagla Abdel Karim
- Last refreshed: 14 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03023319.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing